Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Medexus Pharmaceuticals Inc (MEDXF)

Medexus Pharmaceuticals Inc (MEDXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MEDXF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +22.75%
on 06/10/24
1.4500 -6.88%
on 06/06/24
+0.1803 (+15.41%)
since 05/31/24
3-Month
1.0800 +25.03%
on 04/18/24
1.4660 -7.89%
on 04/29/24
+0.1313 (+10.77%)
since 03/28/24
52-Week
1.0600 +27.39%
on 11/30/23
2.5620 -47.30%
on 09/12/23
-0.0397 (-2.86%)
since 06/30/23

Most Recent Stories

More News
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024

FDA has Accepted for Review the Treosulfan NDAManagement to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024)...

MEDXF : 1.3503 (+1.53%)
MDP.TO : 1.82 (+4.60%)
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26,...

MEDXF : 1.3503 (+1.53%)
MDP.TO : 1.82 (+4.60%)
FDA Accepts for Review Treosulfan NDA Resubmission

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization...

MEDXF : 1.3503 (+1.53%)
MDP.TO : 1.82 (+4.60%)
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®....

MEDXF : 1.3503 (+1.53%)
MDP.TO : 1.82 (+4.60%)
Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the...

MEDXF : 1.3503 (+1.53%)
MDP.TO : 1.82 (+4.60%)
FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age groupToronto, Ontario and Chicago, Illinois--(Newsfile...

MEDXF : 1.3503 (+1.53%)
MDP.TO : 1.82 (+4.60%)
Medexus Announces Fiscal Q3 2024 Results

Fiscal Q3 2024 revenue of $25.2 million, Operating income of $1.6 million, and Adjusted EBITDA* of $3.2 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 8, 2024Toronto,...

MEDXF : 1.3503 (+1.53%)
MDP.TO : 1.82 (+4.60%)
Medexus Schedules Third Fiscal Quarter 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February...

MEDXF : 1.3503 (+1.53%)
MDP.TO : 1.82 (+4.60%)
Health Canada Accepts for Review Medexus's New Drug Submission for Topical Terbinafine

Topical terbinafine has been widely used in other markets to treat fungal nail infectionsIf and when approved, the product will enter the topical fungicides market that is estimated to be C$88 million...

MEDXF : 1.3503 (+1.53%)
MDP.TO : 1.82 (+4.60%)
Medexus Announces Strong Fiscal Q2 2024 Results, Including Quarterly Revenue of US$30.3 Million

Fiscal Q2 2024 revenue reflects a 9.4% increase over fiscal Q2 2023, demonstrating strong revenue growth and continued overall performanceManagement to host conference call at 8:00 AM Eastern time on Thursday,...

MEDXF : 1.3503 (+1.53%)
MDP.TO : 1.82 (+4.60%)

Key Turning Points

3rd Resistance Point 1.3833
2nd Resistance Point 1.3567
1st Resistance Point 1.3433
Last Price 1.3503
1st Support Level 1.3033
2nd Support Level 1.2767
3rd Support Level 1.2633

See More

52-Week High 2.5620
Fibonacci 61.8% 1.9882
Fibonacci 50% 1.8110
Fibonacci 38.2% 1.6338
Last Price 1.3503
52-Week Low 1.0600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar